Lyell Immunopharma

Lyell Immunopharma is a cell therapy company dedicated to mastering the function of immune cells. They focus on advancing the science of T-cell differentiation, function, and specificity in order to develop drugs for treating human diseases. Lyell has already established two proprietary cell reprogramming technology platforms (Gen-R, Epi-R), which primarily aim to fundamentally enhance T-cell efficacy and address two major challenges hindering T-cell therapies for solid tumors: T-cell exhaustion and lack of activity.